The Committee for Medicinal Products for Human Use (CHMP) decided that PhotoBarr’ s benefits are greater than its risks when used in photodynamic therapy for the ablation of high-grade dysplasia in patients with Barrett’ s oesophagus.
Inimravimite komitee jõudis otsusele, et PhotoBarri kasulikkus selle kasutamisel fotodünaamilises ravis tugeva düsplaasia ablatsiooniks Barretti söögitoruga patsientidel on suurem kui ravimiga kaasnevad riskid.